Premas Biotech, Akers Bio announce progress of COVID-19 vaccine development
India, April 7 -- US based Akers Biosciences, Inc., a developer of rapid health information technologies, has announced that its collaboration with Gurugram based Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate.
The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selection of the right host; third, the insertion of the gene into the host; and fourth, the verification that the clone has the right gene, and all characteristics are correct.
Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, commented...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.